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Transcription factor Hes1.Notch signaling is a highly conserved signal transduction pathway that regulates stem cell maintenance and
differentiation in several organ systems. Upon activation, the Notch receptor is proteolytically processed, its
intracellular domain (NICD) translocates into the nucleus and activates expression of target genes. Output,
strength and duration of the signal are tightly regulated by post-translational modiﬁcations. Here we review
the intracellular post-translational regulation of Notch that ﬁne-tunes the outcome of the Notch response. We
also describe how crosstalk with other conserved signaling pathways like the Wnt, Hedgehog, hypoxia and
TGFβ/BMP pathways can affect Notch signaling output. This regulation can happen by regulation of ligand,
receptor or transcription factor expression, regulation of protein stability of intracellular key components,
usage of the same cofactors or coregulation of the same key target genes. Since carcinogenesis is often dependent
on at least two of these pathways, a better understanding of their molecular crosstalk is pivotal.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A tightly regulated spatio-temporal control of gene expression is
required during embryogenesis and post-natal development, and in
adult homeostasis and tissue repair. Cell–cell communication is used
to properly coordinate and modulate gene expression programs by
assembly and disassembly of coactivator and corepressor complexes.
A fairly low number of highly conserved signaling pathways have
evolved that are re-used in different body locations and processes, and
mediate such communication events. Among these, the Notch, Wnt,
Hedgehog, hypoxia and TGFβ/BMP signaling pathways play critical
roles in both embryonic and adult life. When these pathways still
function, but are unbalanced, they often lead or contribute to disease
development. The binding of ligands to their cognate receptors triggers
an intracellular event that results in the accumulation/stabilization of
intracellular signaling effectors and/or in their activation, mainly via
post-translational modiﬁcations. Ultimately, the event culminates
with the translocation of signaling effectors to the nucleus where they
bind to enhancer regions mediating the (dis)assembly of coactivator-giessen.de (T. Borggrefe).
. This is an open access article undercomplexes in a cell-type and locus-speciﬁc manner. Importantly, these
signaling pathways do not operate in isolation, indeed they crosstalk
to each other to ensure a more accurate and robust control of gene
expression programs and resulting cellular responses
Here, we review the current knowledge on post-translational
regulation of the intracellular domain of Notch (NICD, also known as
Notch-IC). We subsequently discuss how the Wnt, Hedgehog, hypoxia
and TGFβ/BMP signaling pathways impact on Notch signaling, with a
focus on the molecular mechanisms of action.
2. Introduction to Notch signaling
Almost a hundred years ago, Thomas Hunt Morgan discovered the
ﬁrst Notchmutant, a strain of fruit ﬂies with “notches” at the margin of
theirwing blades. Notch signaling has subsequently been shown to be es-
sential for embryonic and post-natal development and regulate diverse
cellular processes, including stem cell maintenance, cell differentiation
and cell death [1–3]. Activation of the Notch signaling pathway requires
cell–cell contact between a Notch family ligand-presenting cell, which
triggers then the cognate Notch receptor (Fig. 1). Receptor–ligand inter-
action results in cleavage events catalyzed by extracellular ADAM
metalloproteases [4,5] and an intracellular γ-secretase-containingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Scheme of the Notch signal transduction cascade. Ligand binding to the Notch receptor results in two proteolytical cleavages that release ﬁrst the still membrane-bound NotchΔE
and subsequently the Notch Intracellular domain (NICD). NICD translocates into the nucleus where it interacts with the transcription factor RBP-J activating expression of target genes.
Fig. 2. Post-translation regulation of theNotch intracellular domain (NICD) and its interac-
tion network with components of the Wnt, hypoxia and BMP/TGFβ signaling pathways.
(A) Schematic representation of the NICD and its post-translational modiﬁcations. RAM,
RBP-J associated module; ANK, ankyrin repeats; TAD, transactivation domain; PEST,
proline-, glutamine-, serine- and threonine-rich domain. A, acetylation; M, methylation;
U, ubiquitination; P, phosphorylation; H, hydroxylation. (B) Schematic representation
of the interaction network of NICD. NICD interacts with β-catenin [66–69,71,74],
Smad proteins [132,139,140,145,146] and HIF-1α [112]. HIF-1α increases the activity of
the γ-secretase complex (γSC) resulting in enhanced Notch signaling [114]. Double
arrows indicate physical interaction.
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into the nucleus where it interacts with RBP-J (Recombination Signal
Binding protein), also known as CSL (CBF-1, Suppressor of Hairless,
Lag-1), building up a trimeric coactivator complex composed of RBP-J,
MAML1 (Mastermind-like 1) and NICD itself [7–10], together with ad-
ditional coactivators (Fig. 1). The Notch coactivator complex facilitates
histone acetylation leading to the expression of target genes. MAML1
interacts with the ankyrin repeats within NICD, stabilizes the interac-
tion of the dimeric NICD/RBP-J complex [7], and recruits the histone
acetyltransferase p300 [11] required for acetylation of histone proteins
and, as a consequence, opens-up the chromatin. MAML1 also regulates
the activity of p300 by increasing its autoacetylation and hence its
transcriptional activity [12]. However, at the same time p300 acetylates
MAML1 thereby destabilizing the MAML1-p300 interaction [13],
suggesting a negative feedback loop that regulates the assembly and
disassembly of the MAML1/p300 complex to terminate transcriptional
responses to Notch. The MAML1-p300 dimeric complex regulates
the stability of the Notch coactivator complex also via acetylation of
the NICD itself, an event that counteracts the ubiquitin-dependent
proteasomal degradation of the NICD [14]. In addition to RBP-J/NICD/
MAML1 and p300, the RNA helicase Ddx5 [15,16] and the long non-
coding RNA (lncRNA) steroid receptor coactivator (SRA) [15] were
shown to be part of the coactivator complex and required for p300
recruitment at Notch-dependent enhancer sites.
2.1. Regulation of the NICD by post-translational modiﬁcations
Mutations that increase the half-life of NICD have been linked to
leukemia [17], illustrating how tightly the amplitude and duration of
the Notch response need to be controlled for proper tissue homeostasis.
The Notch response is tuned by post-translational modiﬁcations of the
NICD (Fig. 2A and Table 1) that regulate its half-life and hence the
NICD-dependent transcriptional output.
Structurally the NICD is characterized by a RAM (RBP-J associated
module) domain and ankyrin (ANK) repeats (Fig. 2A), which both are
required for signal transduction. The RAM domain contains several
nuclear localization signals (NLSs) and together with the ANK repeats
it represents the binding module for RBP-J. At the C-terminus the
NICD also contains a transactivation domain (TAD) followed by a
Table 1
Post-translational modiﬁcations within the human and mouse NICD. Residues are shown independently if their post-translational modiﬁcation has been described in human or mouse.
Numbering is accordingly to NP_060087.3, NP_032740.3, NP_077719.2, NP_035058.2, NP_000426.2, NP_032742.1, Q99466.2 and P31695.2. Not described (ND); not conserved (NC).
Amino acid sequences are referred to mouse unless speciﬁed. Bold letters indicate the modiﬁed amino acid.
Protein Modiﬁcation Sequence Mouse Human Reference(s) Writer Eraser
Notch-1 Acetylation GFKVS K 1764 K 1774 [38] PCAF, p300 SIRT1
ASKKK K 1770 K 1780 [38] PCAF, p300 SIRT1
SKKKR K 1771 K 1781 [38] PCAF, p300 SIRT1
KKKRR K 1772 K 1782 [38] PCAF, p300 SIRT1
GLKPL K 1785 K 1795 [38] PCAF, p300 SIRT1
AAKRL K 1935 K 1945 [38] PCAF, p300 SIRT1
NNKEE K 2050 NC [38] PCAF, p300 SIRT1
TAKVL K 2068 K 2078 [38] PCAF, p300 SIRT1
NLKSA K 2140 K 2150 [14] p300 ND
QGKKA K 2146 K 2156 [14,38] PCAF, p300 SIRT1
GKKAR K 2147 K 2157 [14,38] PCAF, p300 SIRT1
ARKPS K 2150 K 2160 [14,38] PCAF, p300 SIRT1
STKGL K 2154 K 2164 [14,38] PCAF, p300 SIRT1
GSKEA K 2161 K 2171 [14,38] PCAF, p300 SIRT1
EAKDL K 2164 K 2174 [14,38] PCAF, p300 SIRT1
DLKAR K 2167 K 2177 [14] p300 ND
RRKKS K 2171 K 2181 [14] p300 ND
RKKSQ K 2172 K 2182 [14] p300 ND
Hydroxylation DANIQ N 1945 N 1955 [40,41,42] FIH ND
DVNAV N 2012 N 2022 [40,41,42] FIH ND
Methylation GSRLA R 2253 R 2263 [44] CARM1 ND
PPRLS R 2262 R 2272 [44] CARM1 ND
LPRLQ R 2303 R 2313 [44] CARM1 ND
PLRPG R 2317 R 2327 [44] CARM1 ND
NTRLA R 2361 R 2372 [44] CARM1 ND
Phosphorylation EDSVG S 1781 S 1791 [165,166] ND ND
NASDG S 1791 S 1801 [35] aPKCζ ND
APTPP T 1851 T 1861 [167] ND ND
LETGN T 1887 T 1897 [34,168] CKII ND
GNSEE S 1890 S 1900 [34,168] CKII ND
GSYET Y 2064 Y 2074 [169] ND ND
VRSPQ S 2111 S 2121 [31] NLK ND
GGTPT T 2122 T 2132 [33] GSK3β ND
TPTLS T 2124 T 2134 [33] GSK3β ND
TLSPT S 2126 S 2136 [31,33] NLK, GSK3β ND
SPTLC T2128 NC [33] GSK3β ND
LCSPN S 2131 S 2141 [31] NLK ND
KPSTK S 2152 S 2162 [166] ND ND
DSSSM S 2184 S 2194 [21] CDK8 ND
MLSPV S 2188 S 2198 [21,31] CDK8, NLK ND
VASPP S 2205 S 2215 [31] NLK ND
LPSPF S 2211 S 2221 [31] NLK ND
QQSPS S 2216 S 2226 [31] NLK ND
FLTPS T 2487 T 2511 [25,27] CDK3, CDK19 ND
TPSPE S 2489 S 2513 [21,27,28] CDK3, CDK8, CDK19 ND
PESPD S 2492 S 2516 [21,27,28] CDK3, CDK8, CDK19 ND
QWSSS S 2497 S 2521 [30] ND ND
WSSSS S 2498 S 2522 [30] ND ND
SSSSP S 2499 S 2523 [30] ND ND
SSSPH S 2500 S 2524 [30] ND ND
ISSPP S 2514 S 2538 [21] CDK8 ND
Ubiquitination GLKPL K 1785 K 1795 [170] ND ND
ETKKF K 1811 K 1821 [171] ND ND
Notch-2 Hydroxylation DANAQ N 1905 N 1904 [40,41,42] FIH ND
DVNAV N 1972 N 1971 [40,41,42] FIH ND
Phosphorylation HGSLW1 NC S 1708 [172] ND ND
GFTLR T 1718 T 1716 [172–174] ND ND
DSSNH S 1724 S 1722 [175] ND ND
LLSEE1 S 1780 S 1778 [172–174,176–181] ND ND
RHTPS T 1803 T 1802 [173] ND ND
TPSLA S 1805 S 1804 [165,173,174] ND ND
ALTPP T 1809 T 1808 [173,177,182] ND ND
GCTPL T 1831 T 1830 [172,177] ND ND
LASLR S 1837 S 1836 [177] ND ND
GGSSD S 1842 S 1841 [183] ND ND
GSSDL S 1843 S 1842 [184] ND ND
DLSDE S 1846 S 1845 [173,174,181,183] ND ND
NVTPS T 2069 T 2068 [37] GSK3β ND
TPSPP S 2071 S 2070 [37,173,177,182,185] GSK3β ND
PGTVL T 2075 T 2074 [37,173,177] GSK3β ND
LTSAL S 2079 S 2078 [36,177] ND ND
ALSPV S 2082 S 2081 [173,174,177,185] ND ND
(continued on next page)
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Table 1 (continued)
Protein Modiﬁcation Sequence Mouse Human Reference(s) Writer Eraser
NRSFL S 2091 S 2090 [180] ND ND
FLSLK S 2094 S 2093 [37,177] GSK3β ND
KHTPM T 2098 T 2097 [173,177,180] ND ND
PTSLP S 2116 S 2115 [166,172,177,180] ND ND
MSTQR T 2298 T 2296 [172] ND ND
SMYQI Y 2342 Y 2340 [169] ND ND
YPTPP T 2387 T 2385 [172] ND ND
PPSQH S 2390 S 2388 [172] ND ND
QVYA Y 2472 Y 2470 [169,172] ND ND
Ubiquitination KRKHG K 1707 K 1705 [186] ND ND
Notch-3 Acetylation GHKGR K 1692 K 1691 [39] p300 ND
EAKRL K 1731 K 1730 [39] p300 ND
Hydroxylation DTNAQ N 1867 N 1866 [40,41,42] FIH ND
DVNAV N 1934 N 1933 [40,41,42] FIH ND
Methylation WARLP R 2174 R 2174 [187] ND ND
Phosphorylation GFSLH1 NC S 1681 [177] ND ND
PRSPS S 2033 S 2032 [177] ND ND
Ubiquitination LHKDI K 1685 K 1684 [186] ND ND
Notch-4 Methylation RPRGG R 1850 R 1871 [187] ND ND
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and threonine-rich (PEST) domain, that destabilizes the NICD itself
[18] (Fig. 2A). Several mutations or truncations that impair the function
of the C-terminal PEST domain have been reported in cancer [17,19,20].
Phosphorylation of the NICD-1 (see Table 1) is mediated by several
kinases and among them the cyclinC/cyclin-dependent kinase 8
(CycC/CDK8) complex plays a key role [21]. The CycC/CDK8 complex
targets serine residues located within the PEST domain of NICD-1 and
supports NICD-1 ubiquitination by Fbw7/Sel10 and its subsequent
degradation [21–27]. Mutations that impair the function of Fbw7/
Sel10 co-occur with Notch mutations in T-acute lymphoblastic
leukemia (T-ALL) [25,28] and recently it was shown that NICD-3 itself
indirectly regulates the levels of Fbw7/Sel10 via miR-223 in T-ALL cell
lines [29]. Additionally, the stability of NICD-1 is regulated via phosphor-
ylation by unknown kinase(s) within its highly conserved sequence
WSSSSP [30], and additional serine residues are phosphorylated by
Nemo-like kinase (NLK) [31] and see Table 1]. Phosphorylation of the
NICD-1 is also mediated by the Down-syndrome-associated kinase
DYRK1A [32], glycogen synthase kinase 3β (GSK-3β) [33], casein kinase
II (CKII) [34] and atypical protein kinase Cζ (aPKCζ) [35]. Furthermore,
phosphorylation does not exclusively occur on the NICD-1, but also on
other Notch family members. For example, NICD-2 phosphorylation is
mediated by unknown kinase(s) at a highly conserved serine (S2078)
[36]. Additional serines and threonines within NICD-2 are again phos-
phorylated by GSK-3β [37].
Acetylation is also an important modiﬁcation of the NICD. Using liq-
uid chromatography–tandem mass spectrometry analysis 14 different
acetylation sites were identiﬁed within the murine NICD-1 [38] and
see Table 1]. The acetyltransferases p300 and PCAF, but not Tip60
(also known as KAT5), acetylate NICD-1, and these events are dynami-
cally regulated by the deacetylase Sirt1. However, it remains unclear
which of the 14 lysines are acetylated by p300 and/or PCAF and which
ones are deacetylated by Sirt1. Functionally, the acetylation of NICD-1
prevents its ubiquitination [14,38], supporting the hypothesis of a
‘Notch code’where a speciﬁcmodiﬁcation of NICDhas an impact on fur-
ther post-translational modiﬁcations and ﬁnally on its turnover. It re-
mains to be seen how the acetylation of the NICD-1 inﬂuences its
ubiquitination; itmight occur in three differentmodalities: 1) the acetyl
mark might change the NICD-1 conformation, masking its
ubiquitination site(s); 2) the acetyl-lysine might mask the docking
site for enzymes of the ubiquitin pathway, preventing their binding;
and 3) a combination of the two previous mechanisms.
Acetylation of the intracellular domain of Notch-3 has also been
reported. In particular, NICD-3 is acetylated on lysines 1692 and 1731
by p300 (but not Tip60), and treatment with the histone deacetylaseinhibitor Trichostain A (TSA) increases its acetylation [39]. Surprisingly,
the effect of NICD-3 acetylation on protein stability is opposite to that
observed for NICD-1 as exempliﬁed by the observation that acetylation
of NICD-3 increases its ubiquitination and, as a consequence, decreases
its stability and transcriptional activity [39]. The acetylation/
ubiquitination crosstalk on NICD-3 protein is poorly characterized, but
importantly treatment with TSA prevents T-ALL development in
a Notch-3-dependent T-ALL mouse model, opening the road to the
pharmacological use of HDAC inhibitors in human T-ALL treatment [39].
Notch-1, Notch-2 and Notch-3 have been described to be hydroxyl-
ated by factor inhibiting HIF (FIH) at two highly conserved asparagine
residues located within the ANKs of NICD [40–42] and see Table 1].
NICD hydroxylation seems to inﬂuence neither its interaction with
RBP-J or with the NICD interactors SKIP (Ski-interacting protein) and
Deltex. However, these conclusions are based only on the ANK repeats
of Notch and not on the entire NICD, a condition that does not reﬂect
the physiological context [40]. Thus, the function of NICD hydroxylation
remains to be further investigated.
Interestingly, proline-isomerization of the Notch1 protein, mediated
by the prolyl-isomerase Pin1, regulates proteolytic cleavage at the plas-
ma membrane and transcriptional activity of the NICD-1 [43]. Pin1
mRNA is also upregulated by Notch activation, establishing a positive
loop that ampliﬁes Notch-1 dependent signaling [43].
Five arginine methylation sites were identiﬁed within the TAD
domain of Notch-1 using a HeavyMethyl SILAC approach [44] and see
Table 1]. This methylation is regulated by the arginine methyltransfer-
ase CARM1 (also known as PRMT4), which has been linked to Notch
transcriptional responses [45]. CARM1 localizes to the enhancer regions
of theNotch target genes preTCRα, Gm266,Hes1 and CD25 and regulates
also the turnover of NICD-1. Mutation of all ﬁve arginines to alanines
(NICD-1 5RA) impairs the ubiquitination of NICD-1 and stabilizes the
protein [44]. Surprisingly, the stabilization of the 5RA mutant does not
result in a signiﬁcant increase of its transcriptional activity compared
to the control NICD-1 [44]. This result is in line with previous observa-
tions [23] and is explained by a mathematical model wherein the
normal NICD-1 produces a short, strong transcriptional pulse, whereas
theNICD-15RAmutant results in aweaker but prolonged response [44].
Finally, NICD ubiquitination regulates its proteasomal-dependent
turnover and as consequence has a strong impact on its transcriptional
activity. In addition to Fbw7/Sel10 the E3 ubiquitin ligase Itch also
causes ubiquitination and modulates turnover of the NICD-1 [46–49].
Interestingly, the E3 ubiquitin ligase Mdm2 was shown to support
protein degradation of NICD-4 [50], whereas it potentiates the transcrip-
tional activity of NICD-1 [51], suggesting that Mdm2 plays opposing
functions on the different Notch family members.
307T. Borggrefe et al. / Biochimica et Biophysica Acta 1863 (2016) 303–313The homo-dimerization of the NICDwas shown to be a critical step to
support transcription [52,53]. In vivo, it is required for leukemogenesis
and T-cell maturation but dispensable for T-cell speciﬁcation [54]. Struc-
tural studies have identiﬁed lysine 1945, glutamic acid 1949 and arginine
1984 as key residues for the Notch dimerization [52]. One can hypothe-
size that the post-translational modiﬁcation of these or ﬂanking residues
can affect the dimerization and thereby theduration ofNotch-dependent
transcriptional responses. Surprisingly however, the Notch dimerization
is only required to induce a subset of Notch target genes like c-Myc,
preTCRα and Nrarp, which contain two RBP-J binding sites oriented
head-to-head and spaced by 16 bp in their enhancer regions [52–54].
Hes1 is a Notch target gene that can be induced in a Notch-
dimerization independent fashion: a dimerization-defective Notch
mutant is still able to induce Hes1 expression, albeit to a lower extent
when compared to the wild-type Notch [53,54]. This result might be ex-
plained by the presence of both monomeric and dimeric Notch (RBP-J-
bound) sites at theHes1 locus. It further suggests the fascinating hypoth-
esis that post-translational modiﬁcations of NICD might prevent its
homo-dimerization while leaving the transcriptional regulation by mo-
nomeric NICD intact and hence affecting not only the duration, but also
the strength of transcription.
2.2. Crosstalk between Notch and Wnt signal transduction pathways
The Wnt signaling pathway regulates a large variety of biological
processes such as the self-renewal capacity of stem cells [55], and
T-cell development and differentiation [56]. In the absence of Wnt,
the β-catenin destruction complex, composed of APC (adenomatous
polyposis coli), Axin, GSK3β and casein kinase I (CKI), regulates the
cytosolic concentration of β-catenin via phosphorylation of β-catenin
and consequent proteasomal degradation. The binding of secreted
Wnt ligands to the transmembrane receptor Frizzled that cooperates
with the coreceptor LRP5/6, causes the recruitment of Dishevelled
(Dvl) that supports the dissociation of the β-catenin destruction
complex by sequestering Axin to the plasma membrane (Fig. 3A). ThisFig. 3. Scheme of theWnt-, Hedgehog-, hypoxia- and TGFβ/BMP signal transduction cascades. (A
causes the sequestration of theβ-catenin destruction complex to the plasmamembrane via inte
a consequence translocates into the nucleus, interacts with the transcription factor TCF/LEF and
(Ptch1/2) which leads to release of Smoothened and the subsequent proteolytic cleavage of Gli
(C) Upon hypoxia the hydroxylases FIH and PHDs can no longer function, resulting in activa
and activate expression of target genes. (D) Binding of TGFβ (or BMP) to their respective rec
Phosphorylated Smads/4 subsequently translocate to the nucleus to activate TGFβ (or BMP) taleads to the cytosolic accumulation of β-catenin, which translocates
ultimately into the nucleus, and dimerizes there with transcription
factors TCF (T-cell factor)/LEF (lymphoid enhancer factor), leading to
activation of target genes [57] and Fig. 3A].
The β-catenin destruction complex plays a key role in the ﬁne-
tuning of theWnt signaling pathway through regulation of the stability
ofβ-catenin.Mutations that impair the activity of theβ-catenin destruc-
tion complex have been linked to several types of cancer. For example,
mutations in APC or AXIN have frequently been observed in colorectal
cancer [58–60]. Such mutations compromise the activity of the β-
catenin destruction complex and result in accumulation of β-catenin
with consequent aberrant activation of the pathway. Not surprisingly,
mutations in β-catenin that dysregulate the phosphorylation of the
protein and hence degradation, are frequently observed in colorectal
cancer too [61].
The Notch andWnt signal transduction pathways can regulate each
other and hence affect their transcriptional output [62]. First, there is
genetic evidence for Notch and Wnt signaling pathways act together
during wing development in Drosophila. Of note, the enhancer of the
Notch target gene Vestigial in Drosophila is synergistically activated by
Notch and Wnt signaling [63]. In mouse, the Wnt pathway was shown
to regulate the expression of the Notch ligand Delta-like1 (Dll1), which
itself is a Notch target gene [64] and Fig. 4]. Importantly, the Notch
target gene Hes1, which encodes a strong basic helix–loop–helix (bHLH)
transcriptional repressor, is also regulated by β-catenin-mediated Wnt
signaling [65–67] and Fig. 4]. Furthermore, biochemical studies revealed
that the direct interaction between β-catenin and Notch-1 (Fig. 2B) re-
duces theubiquitinationofNotch-1,which results in increased expression
of Hes1 [68]. In another study the Notch/RBP-J/β-catenin interaction was
described to occur at several target genes and to synergistically support
angiogenesis [69].
The serine/threonine kinase GSK3β, which mediates phosphoryla-
tion of β-catenin and boosts thereby its degradation, represents an im-
portant hub in Wnt and Notch signaling crosstalk (Fig. 4). Remarkably,
GSK3β phosphorylates serine and threonine residues of NICD-1, leading) The binding of the solubleWnt ligand to the receptor Frizzled and the coreceptor LRP5/6
ractionswith Dishevelled (Dvl). This event results in the stabilization of β-cateninwhich as
supports expression of target genes. (B). The Hedgehog ligand binds to receptor patched
into Gli-A. Gli-A subsequently translocates into the nucleus and activates gene expression.
tion of HIF-α proteins that migrate into the nucleus where they dimerize with HIF-1β
eptor complexes leads to the phosphorylation of cytoplasmic Smad2/3 (or Smad1/5/8).
rget genes. For simplicity, only the TGFβ signaling cascade is shown.
Fig. 4.The cross-regulation ofNotch signaling. Activation of theNotch signaling pathway leads to activation ofHes1gene. TheWnt signalingpathway crosstalkswithNotch via activation of
Notch target genes likeHes1 [37,65–69] or of Notch signaling components like Notch receptors [64,67,83,84] and ligands [64,84]. Furthermore, GSK-3β potentiates Notch-dependent gene
expression via phosphorylation of Notch-1 [33,70] but can also reduce the transcriptional activity of Notch-2 [37] (not represented). The Hedgehog (Hh) signaling pathway induces
activation of Hes1 Notch target gene [92–95] and of Notch receptors [94,95] and ligands [94,97]. Hypoxia crosstalks with the Notch signaling pathway via induction of Notch ligands
[109–111,121–123,125] and receptors [122] and common target genes like Hes1 [111,112,114,121–123,125,127]. Furthermore, under normoxia FIH crosstalks with Notch via NICD
hydroxylation [40–42]. Similar mechanisms are used by the BMP/TGFβ signaling pathway to crosstalk with Notch. For example it can induce expression of ligands
[128,130,133,134,136,142,155], receptors [155] or of Notch target genes like Hes1 [128,129,133–136,140–142]. For simplicity, ligands or receptors that are repressed within the network
are omitted. Dotted lines indicate a post-translational-dependent crosstalk whereas red arrows indicate a gene induction-dependent crosstalk. Similar mechanisms can be used to control
the expression of other Notch target genes such as Hey1, Hey2 and/or HeyL.
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activities [33,70]. GSK3β was also reported to phosphorylate NICD-2
but, in contrast to NICD-1, the GSK3β-dependent NICD-2 phosphoryla-
tion results in decreasing its transcriptional activity [37]. Thus,
phosphorylation of either NICD-1 or NICD-2 can potentially have
different outcomes and this might also be cell-type speciﬁc.
Notch tethers β-catenin and hence negatively regulates the latter's
stability [71–73]. Notch-1 loss-of-function leads to activation of
β-catenin and increases the transcriptional activity of a β-catenin-
responsive reporter construct, suggesting that Notch dampens β-
catenin-mediated responses to Wnt [74].
The non-canonical Wnt/Ca2+ pathway cooperates also with Notch
signaling. In the non-canonical Wnt/Ca2+ pathway, the activation of
the receptor Frizzled activates a signaling cascade that culminates
with the release of Ca2+ from the endoplasmic reticulum, which
activates the calcium calmodulin-dependent protein kinase II (CaMKII)
[75]. Activation of CamKII by Wnt5a, a representative ligand that
activates the β-catenin-dependent and β-catenin-independent
pathways, triggers the phosphorylation of the RBP-J-interacting core-
pressor SMRT (silencingmediator of retinoic acid and thyroid hormone
receptor) on serine 1407, resulting in increased promoter activity of a
Notch-responsive reporter construct [76].
Conversely, there is also evidence that Notch synergizes with Wnt
signaling during T-cell development: Notch upregulates the mRNA
levels of the canonical Wnt-transcription factor TCF1 [77,78]. Further-
more, the Wnt-receptor Frizzled is activated by Notch signaling in
dendritic cells, stimulating their differentiation [79]. The Notch target
gene Nrarp (Notch-regulated ankyrin repeat protein) not only acts as
a negative feedback regulator of Notch, but also as a positive regulator
ofWnt [80,81]. Nrarp orchestrates its positive function onWnt signaling
via stabilization of the transcription factor LEF1, leading to increase in
LEF1-dependent promoter activity [81,82].
Finally, it is important to note the biological importance of
the Notch-Wnt crosstalk in carcinogenesis: Wnt signaling positively
regulates the expression of Notch-2 in colorectal cancer cells [83] andinduces the expression of the Notch ligand Jag1 in ovarian cancer [84]
(Fig. 4).
Wnt and Notch signaling often act synergistically. However, in
another context, Wnt can also negatively regulate Notch activity. Dvl
functionally integrates Wnt and Notch regulation. Overexpression of
Dvl but not overexpression of β-catenin reduces the promoter activity
of a Notch-responsive reporter construct in the presence of a Notch
signal [85]. The inhibitory effect of Dvl is relevant in vivo as loss-of-
function of Dvl results in a decrease of ciliated cell precursors, which is
negatively regulated by Notch signaling. The inhibitory effect of Dvl is
mediated via its physical interaction with RBP-J, thereby reducing the
transcriptional activity of RBP-J [85]. Alternatively, or in addition, it
has also been reported that Dvl interacts withNotch receptor regulating
its endocytosis in Drosophila [86,87].
2.3. Crosstalk between Notch and Hedgehog signaling
The Hedgehog (Hh) signaling pathway is initiated by the binding of
Hh family ligands to their receptors Patched (Ptch1/2), a 12-pass trans-
membrane protein. This event derepresses the 7-pass transmembrane
protein Smoothened (Smo), which initiates additional steps to activate
the transcription factor Gli (glioma-associated oncogene) (Fig. 3B).
Proper Hh signaling is crucial for correct embryogenesis, also of mam-
mals. In post-natal life, the Hh pathway is spatially restricted and its
proposed role is the induction of proliferation of adult stem cells,
which are required for tissuemaintenance and repair [88,89].Moreover,
Hh signaling is particularly important for the development of tumor-
stroma [90,91].
Expression of Hes1 can be induced by the Hh signaling pathway in a
Notch-independent manner in multi-potent mesodermal cells [92] and
retinal explants [93] (Fig. 4). This induction requires the activity of both
Gli1 [94] and Gli2 [93,95], and binding of Gli2 to the Hes1 locus was
revealed by ChIP [93], suggesting a direct regulation of Hes1 by the Hh
signaling pathway. On the other hand, another study has demonstrated
that Hes1 represses Gli1 in glioblastoma-derived neurospheres via
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still unclear whether Gli1 and Hes1 regulate each other's transcription
in the same cell type, but if they do so, it is tempting to speculate that
the cooperative feedforward and antagonistic feedback interactions
lead to sharp and transient pulses of signaling of both pathways. In
line with these observations the Notch ligand Jagged1 and Gli2 regulate
each other's mRNA levels in a positive manner in ovarian cancer cell
lines; surprisingly, the regulation of Gli2 by epistatic Jagged1 occurs in
a Notch-independent manner [97]. Furthermore, activation of the
Notch signaling pathway induces the expression of Sonic Hedgehog
(SHh) in neural stem cells [98], while induction of Gli1 results in
upregulation of both Notch ligand Jag1 and Notch-1 receptor mRNAs
in different regions of the brain [94] and Fig. 4]. Taken together, there
is numerous evidence for crosstalk between the Hh and Notch path-
ways, with the majority of reports describing a positive interaction.
Recently, novel mechanistic insight into how Notch activity could
increase Hh signaling effectiveness was provided: Notch regulates
transport processes in and out of the primary cilium, a signaling center
crucial for proper Hh pathway coordination [99]. Since Ptch1 and Smo
localize to the cilium, Notch sets the overall cellular threshold for Hh
responsiveness by impacting on the ciliary transport of Ptch1 and/or ad-
ditional ciliary signaling molecules [100]. In this regard it is intriguing
that Notch-3 and Presenilin2, a subunit of the γ-secretase complex,
also localize to/around primary cilia, e.g. in keratinocytes [101,102].
Therapeutically, the Notch-Hh crosstalk seems to represent a sensi-
tive node for targeted intervention. Combinatorial inhibition of Notch
and Hh signaling reduces the viability of both CD133+ glioma stem
cells [103], hormone-refractory prostate cancer cell lines [104] and
T-ALL cell lines withNotchmutations [105]. In contrast, Notch signaling
cooperates with miR-7 to silence Hh signaling, thereby promoting
tumorigenesis in Drosophila [106]. However, it is currently unclear if
this interaction loop is regulating tumorigenesis also in humans.
2.4. Crosstalk of Notch with hypoxia signaling
Compared to theNotch,Wnt, Hh and TGFβ/BMP signaling pathways,
the hypoxia pathway does not require secreted or transmembrane pro-
teins, instead it senses oxygen concentrations. Oxygen represents the
key cofactor for both prolyl-hydroxylases (PHDs) and factor inhibiting
HIF (FIH). Once active, FIH and PHDs hydroxylate the transcription fac-
tors hypoxia-inducible factor α (HIF-1α and HIF-2α) at asparagine and
proline residues, respectively. While FIH-dependent hydroxylation of
HIF-α proteins prevents their interaction with p300, the PHD-
dependent hydroxylation does target HIF-α for proteasomal degrada-
tion via von Hippel–Lindau (VHL)-dependent ubiquitination. Under
hypoxia, both FIH and PHDs are inactive, resulting in stabilization of
HIF-α proteins that dimerize with HIF-1β; this complex binds to
hypoxia-responsive elements (HRE) and triggers transcription of target
genes such as Vegf (vascular endothelial growth factor) that leads to
stimulation of angiogenesis [107,108] (Fig. 3C).
One of the ﬁrst evidences for crosstalk between Notch and hypoxia
signaling emergedwhen it was shown that hypoxia leads to an upregu-
lation of the Notch ligand Delta-4 (Dll4)-encoding gene in a HIF-1α-
dependent manner [109,110] and Fig. 4]. The underlying mechanism
was revealed when NICDs were shown to be hydroxylated by FIH
[40–42]. Upon hypoxia, FIH is no longer functional and the hydroxyl-
ation of NICD-1 is signiﬁcantly reduced. Surprisingly, loss-of-function
of FIH does not inﬂuence the transcriptional activity of NICD-1 in lucif-
erase reporter assays [40] even though two independent studies
showed that Notch target genes are induced under hypoxia and that
this induction is dependent on Notch activity [111,112]. In addition,
the loss of FIH function leads to upregulation of the Hey1 Notch target
gene in HUVECs [113]. Two additional reports reveal that the interplay
of Notch andhypoxia has even additional layers of complexity: 1) nucle-
ar HIF1α synergizes with NICD-1 to upregulate a subset of target genes
for Notch and this occurs via a physical interaction between HIF1α andNICD-1 [112 and Fig. 2B]; 2) upon induction of the hypoxic response,
cytoplasmic HIF-1α increases the activity of the γ-secretase complex,
causing a strong increase in the release ofNICDandﬁnally in the expres-
sion of the target gene Hes1 [114] and Fig. 2B].
The crosstalk between Notch signaling and the hypoxia response is
particularly important as Notch signaling is critical in balancing
sprouting angiogenesis [115]. Mice deﬁcient for either Notch receptors
or ligands show severe defects in vascular remodeling [116–118] and
Notch signaling was described to induce the expression of Vegfr-1
gene (encoding VEGF receptor 1) [119] and to repress Vegfr-3 [120].
The Notch-hypoxia crosstalk is relevant for epithelial-to-
mesenchymal transition (EMT) as it potentiates Notch signaling and
increases invasion of breast cancer cells [121], oral squamous cell
carcinoma cell lines [122] and ovarian carcinoma cell lines [123].
Furthermore, the Notch-hypoxia crosstalk contributes to the progres-
sion of prostate cancer [124], invasion of uveal melanoma [125] and
maintenance of glioblastoma stem cells [126,127].
2.5. Crosstalk between Notch and TGFβ/BMP signaling
Members of the transforming growth factor type beta (TGFβ) family,
including bone morphogenetic proteins (BMP), control a plethora of
context-dependent cellular processes in embryogenesis and adult tissue
homeostasis. Ligand–receptor interactions can trigger Smad-dependent
and non-Smad signaling cascades. Here we will only focus on Smad-
mediated responses because crosstalk with the Notch pathway has
been chieﬂy reported for this cascade. Liganded receptor complexes
activate intracellular effector proteins, the receptor-regulated Smads.
Smad1, Smad5 and Smad8 are phosphorylated in response to BMP
signals, while Smad2 and Smad3 become phosphorylated in response
to TGFβ/activin-like signals. Phosphorylation of these Smads leads to
their interaction with the common mediator Smad4, and subsequent
translocation of the complex to the nucleus (Fig. 3D). The Smad
transcriptional complexes then pair with other context-dependent
transcription factors (and cofactors thereof) to regulate hundreds of
genes, with often very distinct gene sets being regulated by the
Smad1/5/8 versus Smad2/3 effectors. There is compelling evidence
that the Notch and the Smad-pathways interact. Several examples will
be discussed here.
BMP and TGFβ signaling can affect Notch ligand and receptor levels.
For example, the activation of the TGFβ signaling pathway inmesenchy-
mal stem cells results in upregulation of theNotch ligand encoding gene
Jag1, which in turn activates the Notch pathway supporting differentia-
tion of smooth muscle cells [128] and Fig. 4], while in ﬁbroblasts the
activation of TGFβ signaling results in repression of Notch-3, which
supports smooth muscle cell differentiation as well [129]. These
observations suggest that stem cells and ﬁbroblasts adopt two different
strategies to differentiate into smooth muscle cells. BMP signaling was
shown to regulate expression of Jag1 directly in endothelial cells
through binding of C-terminally phosphorylated Smad1/5 to GC-rich
SMAD-binding elements in the Jag1 promoter [130]. Though Jag1 is
known to activate the receptor Notch in many cells, Jag1 and Dll4
may exert profound opposite effects. For example, in endothelial cells
their opposite effect can be explained by Jag1-mediated inhibition of
Dll4-Notch signaling critical for sprouting angiogenesis [131].
Notch and TGFβ/BMP signaling cooperatively regulate several Notch
target genes, such as Hey1/2 and Cdh2 [132–134], although activated
Smad1 can also act in a Notch-independent manner to activate the
Hey-1/2 promoters [130,135–138]. NICD and Smad4 cooperate in regu-
lating Cdh2 encoding N-cadherin [139]. ChIP analysis supported that
BMP- as well TGFβ-regulated Smads formed a complex with NICD and
RBP-J, and that TGFβ/BMP enhanced the recruitment of the complex
to the RBP-J binding site on the promoter to transactivate Cdh2 [139].
The Notch target gene Hes1 represents another example of the
Notch-TGFβ crosstalk (Fig. 4); Hes1 is induced by TGFβ [128,129,140,
141] and its proximal promoter is characterized by two conserved
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revealed that the Hes1 promoter is responsive to Smad2, but not
Smad3 in mouse ﬁbroblasts [129], even though the occupancy of
Smad3 at the Hes1 promoter could be revealed by ChIP in human
keratinocytes in another study [142]. This discrepancy likely reﬂects a
context-dependent Smad usage to induce Hes1. BMP-Smads have not
been demonstrated to regulate Hes1 directly, yet overexpression of
the Smad1/5 acknowledged target genes encoding Inhibitor of differen-
tiation proteins (IDs), promotes Hes1 expression in endothelial cells
[133]. ID proteins are potent inhibitors of differentiation of progenitors
of different cell types; they promote cell-cycle progression, delay cellu-
lar senescence, and facilitate migration [143]. These small polypeptides
harbor a helix–loop–helix (HLH)motif that lacks DNA-binding capacity.
They are known tomediate through dimerizationwith E-type basic HLH
(bHLH) DNA-binding transcription factors and hence interfere with the
bHLH-mediated gene regulation [143]. The Hes1 and Hey1 NICD
effectors are potent transcriptional repressors that can also dimerize
with Ids [144]. The ID-Hes1 heterodimer formation might explain how
the negative autoregulation of Hes1 is counteracted by BMP-Smads
[132,133,144].
NICD-1 and NICD-4 were shown to interact with Smad3 [140,145,
146] and Fig. 2B].Whereas theNICD-4/Smad3 interaction has a negative
impact on TGFβ-dependent transcription [146], the NICD-1/Smad3
interaction enhances both TGFβ-dependent and Notch-dependent
transcription of downstream genes [140], which again likely reﬂects
contextual differences.
In the developing heart, Notch signaling initiates EMT in the endo-
cardium of the atrioventricular canal (AVC), triggering valve formation;
both BMP and TGFβ signaling act in concert with Notch to promote
the transition of endothelium to mesenchyme and the mesenchymal
invasiveness in this process [147].
BMP/TGFβ signaling can also antagonize Notch signaling. Remark-
ably, Notch and BMP signaling seem to synergize and to antagonize
each other often in the same cell type, which likely illustrates that
the interplay between positive feedforward and negative feedback
mechanisms is required to control transient, but robust signaling
output. In endothelial cells Smad1/5 induces, in a Notch-independent
manner, expression of the ID genes [143]; these ID proteins contribute
on their turn to sustain Hes1 expression by releasing the negative
autoregulation of Hes1 accumulation [144], so BMPs synergize with
Notch signaling. However, upon increased expression of Hey2, the
Hey2 bHLH protein competes with Hes1 for binding to IDs and targets
the Hey2-ID complexes for proteasomal degradation. The consequently
reduced availability of IDs impacts on Hes1 levels because of increased
autorepression of Hes1 [132,133]. This example illustrates that context
and relative abundance of Hes1, ID and Hey-components can pivot
BMP and Notch between synergy and antagonism [148]. A recent
study in zebraﬁsh showed that in contrast to the cooperative interac-
tions between DLL4/Notch and BMP9/activin receptor-like kinase 1
(ALK1)/Smad1/5 in enhancing arterial Notch target gene expression
in cultured endothelial cells and mice [132–136], abrogation of Alk1
signaling failed to decrease expression of Notch targets, and they uncov-
ered opposing roles of Notch and Alk1 in expression of the Notch target
and arterial marker, Dll4 [137]. This reﬂects probably spatio-temporal
context differences and illustrates that extrapolation of results obtained
even in one cell type or vascular bed should be donewith extreme care.
Very recently, Neuropilin 1 (NRP1) has been shown to link Notch
and TGFβ/BMP signaling [149]. NRP1 is a transmembrane coreceptor
for several unrelated ligands. NRP1 has been shown to function as a
Notch effector and links Notch with TGFβ/Alk5 (the latter being the
type I receptor involved in its signaling) and BMP9/Alk1 signaling to
regulate endothelial competition for the tip position. This Notch effector
is themost critical determinant of tip cell formation and function known
to date.
Notch signaling also affects BMP/TGFβ ligand and receptor levels.
The loss of Notch signaling in mouse embryos causes defects inendocardial EMT in the AVC, which is associated with reduced levels
of TGFβ receptors in endocardium, and loss of TGFβ2 in adjacent AVC
myocardium [150]. Conversely, Notch signaling represses expression
of BMP2 via Hey proteins in the non-AVC myocardium [147].
In different oncogenic settings impaired TGFβ signaling has been
correlatedwith disturbedNotch signaling. Dysfunctional TGFβ signaling
in esophageal adenocarcinoma is associated with increased Notch sig-
naling [151,145], whereas a positive functional cooperation between
Notch and TGFβ was observed in clear cell renal cell carcinoma [152]
and in lung carcinoma [153], suggesting the Notch-TGFβ crosstalk as
an important additional mechanism in carcinogenesis. Finally, the
Notch-TGFβ crosstalk is relevant in kidney diseases [154] and during
TGFβ-induced EMT [142,155].
It must be also considered that the Notch-TGFβ/BMP crosstalk is
not exclusive to Notch-expressing cells, the so-called signal-receiving
cells. In fact it might occur also in cells that express Notch ligands, the
so-called signal-sending cells. In particular, it was shown that the intra-
cellular domain of the Notch ligand Delta supports TGFβ-dependent
transcription in luciferase reporter assays [156].
2.6. Crosstalk between Notch and FGF signaling
Binding of FGF to the FGF receptor (FGFR) leads to receptor dimer-
ization and activating phosphorylation resulting in changes in gene
expression. Crosstalk between Notch and FGF signaling is critical during
somitogenesis, a process required for the correct development of the
body plan [157,158]. Somitogenesis is accompanied by a rhythmic
expression of genes controlled by the Notch, Wnt and/or FGF signaling
pathways and feedback loops and crosstalk among these pathways are
critical to control the rhythmic gene expression and as consequence
somites formation [159]. The rhythmic expression of Hes1 was shown
to be controlled by the FGF signaling pathway in mouse C3H 10 T1/2
cells and to correlate with the phosphorylation of ERK (extracellular
signal-regulated kinase), a kinase downstream of the FGF signaling
pathway [160]. In addition, the oscillating expression of the FGF inhibi-
tor Sprouty4, in mouse presomitic mesoderm (PSM), is synchronized
with the expression of the Notch target lunatic fringe (Lfng) and its
rhythmical expression is dependent on the activity of the Notch target
gene Hes7 [161]. Hes7 encodes for a repressor of transcription and
surprisingly its repressive activity is not required to regulate the basal
expression of Sprouty4 but to regulate its FGF-dependent induction
[161]. Another example of crosstalk between Notch and FGF was
described during asexual reproduction of the polyp Hydra vulgaris. In
this context, Notch signaling is required to restrict the expression zone
of kringelchen, the homolog of FGFR, to the boundary between parent
and bud [162]. Inhibition of Notch signaling leads to a diffuse expression
pattern of kringelchen associated with failure in foot formation and not
completed detachment of the bud from the parent [162].
Notch is known to crosstalk with even more signaling pathways,
which have been extensively reviewed by others [163,164].
2.7. Outlook
The Notch signaling pathway is remarkably simple with just the
trimmed receptor that exerts its function in the nucleus without
intervention of classical second messengers. Yet, this highly conserved
pathway integrates several additional inputs from other signaling
pathways. One such key regulatory node is the post-translational
modiﬁcation of NICD. We reviewed several examples of such cross-
regulation: pathways can regulate each other by physical interaction
(e.g. interaction between NICD and Smads), upregulation of ligands or
receptors (e.g.Wnt regulating Notch ligand levels), common usage of
regulators (e.g. hydroxylase FIH for hypoxia and Notch), coregulation
of shared target genes (e.g. Hes1 regulation by Notch, Wnt, Hh and
BMP/TGFβ). Identiﬁcation of the key regulatory nodes between
pathways will be an important base to design more speciﬁc inhibitors
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combinatorial treatments. In addition, this knowledge is also forming
the base for systems-biology type approaches to predict possible
outcomes of receptor stimulation in a quantitative manner. In addition,
precise biophysical measurements in the dynamic switch-on and
switch-off systems should be used to identify the key regulatory
mechanisms.Transparency document
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